Table 2. Comparison of rucaparib and olaparib results from respective trials.
| Results | TRITON3 trial | PROfound trial | |||||
|---|---|---|---|---|---|---|---|
| Rucaparib | PCSC | P value | Olaparib | PCSC | P value | ||
| PFS in overall population (months), median | 10.2 | 6.4 | <0.001 | 5.8 | 3.5 | <0.001 | |
| PFS BRCA1/BRCA2 (TRITON3) or BRCA1/BRCA2/ATM (PROfound) (months), median | 11.2 | 6.4 | <0.001 | 7.4 | 3.6 | <0.001 | |
| Confirmed ORR (overall population) (%) | 35 | 16 | – | 22 | 4 | – | |
| Confirmed ORR (germline cohort) (%) | 45 | 17 | – | 33 | 2 | <0.001 | |
| OS (months) | 24.3 | 20.8 | 0.21 | 17.5 | 14.3 | – | |
PCSC, physician choice standard of care; PFS, progression-free survival; ORR, objective response rate; OS, overall survival.